1
|
Zhang L, Li Y(H, Kibler K, Kraberger S, Varsani A, Turk J, Elmadbouly N, Aliskevich E, Spaccarelli L, Estifanos B, Enow J, Zanetti IR, Saldevar N, Lim E, Schlievert J, Browder K, Wilson A, Juan FA, Pinteric A, Garg A, Monder H, Saju R, Gisriel S, Jacobs B, Karr TL, Florsheim EB, Kumar V, Wallen J, Rahman M, McFadden G, Hogue BG, Lucas AR. Viral anti-inflammatory serpin reduces immuno-coagulopathic pathology in SARS-CoV-2 mouse models of infection. EMBO Mol Med 2023; 15:e17376. [PMID: 37534622 PMCID: PMC10493584 DOI: 10.15252/emmm.202317376] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Revised: 07/13/2023] [Accepted: 07/14/2023] [Indexed: 08/04/2023] Open
Abstract
SARS-CoV-2 acute respiratory distress syndrome (ARDS) induces uncontrolled lung inflammation and coagulopathy with high mortality. Anti-viral drugs and monoclonal antibodies reduce early COVID-19 severity, but treatments for late-stage immuno-thrombotic syndromes and long COVID are limited. Serine protease inhibitors (SERPINS) regulate activated proteases. The myxoma virus-derived Serp-1 protein is a secreted immunomodulatory serpin that targets activated thrombotic, thrombolytic, and complement proteases as a self-defense strategy to combat clearance. Serp-1 is effective in multiple animal models of inflammatory lung disease and vasculitis. Here, we describe systemic treatment with purified PEGylated Serp-1 as a therapy for immuno-coagulopathic complications during ARDS. Treatment with PEGSerp-1 in two mouse-adapted SARS-CoV-2 models in C57Bl/6 and BALB/c mice reduced lung and heart inflammation, with improved outcomes. PEGSerp-1 significantly reduced M1 macrophages in the lung and heart by modifying urokinase-type plasminogen activator receptor (uPAR), thrombotic proteases, and complement membrane attack complex (MAC). Sequential changes in gene expression for uPAR and serpins (complement and plasminogen inhibitors) were observed. PEGSerp-1 is a highly effective immune-modulator with therapeutic potential for severe viral ARDS, immuno-coagulopathic responses, and Long COVID.
Collapse
Affiliation(s)
- Liqiang Zhang
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Yize (Henry) Li
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
- School of Life SciencesArizona State UniversityTempeAZUSA
| | - Karen Kibler
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Simona Kraberger
- Center of Fundamental and Applied MicrobiomicsBiodesign Institute, Arizona State UniversityTempeAZUSA
| | - Arvind Varsani
- School of Life SciencesArizona State UniversityTempeAZUSA
- Center of Fundamental and Applied MicrobiomicsBiodesign Institute, Arizona State UniversityTempeAZUSA
- Center for Evolution and Medicine, School of Life SciencesArizona State UniversityTempeAZUSA
| | - Julie Turk
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Nora Elmadbouly
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Emily Aliskevich
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Laurel Spaccarelli
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Bereket Estifanos
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Junior Enow
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Isabela Rivabem Zanetti
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Nicholas Saldevar
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Efrem Lim
- School of Life SciencesArizona State UniversityTempeAZUSA
- Center of Fundamental and Applied MicrobiomicsBiodesign Institute, Arizona State UniversityTempeAZUSA
| | - Jessika Schlievert
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Kyle Browder
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Anjali Wilson
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Fernando Arcos Juan
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Aubrey Pinteric
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Aman Garg
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Henna Monder
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Rohan Saju
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Savanah Gisriel
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
- Departments of Pathology & Lab MedicineYale‐New Haven HospitalNew HavenCTUSA
| | - Bertram Jacobs
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
- School of Life SciencesArizona State UniversityTempeAZUSA
| | - Timothy L Karr
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
- Neurodegenerative Disease Research Center & Proteomics Center, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Esther Borges Florsheim
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
- School of Life SciencesArizona State UniversityTempeAZUSA
| | - Vivek Kumar
- New Jersey Institute of TechnologyNewarkNJUSA
| | | | - Masmudur Rahman
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Grant McFadden
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
- School of Life SciencesArizona State UniversityTempeAZUSA
| | - Brenda G Hogue
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
- School of Life SciencesArizona State UniversityTempeAZUSA
- Center for Applied Structural Discovery, Biodesign InstituteArizona State UniversityTempeAZUSA
| | - Alexandra R Lucas
- Center for Personalized Diagnostics, Biodesign InstituteArizona State UniversityTempeAZUSA
- Center of Immunotherapy, Vaccines and Virotherapy, Biodesign InstituteArizona State UniversityTempeAZUSA
| |
Collapse
|